EA199901081A1 - METHODS OF POTENTIATION OF INTERNAL STRAUMUSTINPHOSPHATE - Google Patents
METHODS OF POTENTIATION OF INTERNAL STRAUMUSTINPHOSPHATEInfo
- Publication number
- EA199901081A1 EA199901081A1 EA199901081A EA199901081A EA199901081A1 EA 199901081 A1 EA199901081 A1 EA 199901081A1 EA 199901081 A EA199901081 A EA 199901081A EA 199901081 A EA199901081 A EA 199901081A EA 199901081 A1 EA199901081 A1 EA 199901081A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- estramustine phosphate
- cancer
- intravenous
- cancers
- straumustinphosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
(57) Эстрамустинфосфат представляет собой антимитотическое химиотерапевтическое лекарственное средство с доказанной эффективностью против рака. Это изобретение описывает способы, которые потенциируют терапевтическую пользу внутривенного эстрамустинфосфата. Данное изобретение обеспечивает введение внутривенного эстрамустинфосфата в высокой дозе, превышающей 1300 мг, в виде отдельной дозы. Посредством этого достигается эффективное повышение фармакокинетики эстрамустинфосфата. Изобретение обеспечивает, кроме того, внутривенное введение эстрамустинфосфата для применения в комплексных программах с другим химиотерапевтическим агентом. Терапевтические преимущества, достигаемые с использованием внутривенной композиции эстрамустинфосфата, применимы в лечении различных раковых опухолей, в том числе рака предстательной железы, рака молочной железы, рака легкого, колоректального рака, рака поджелудочной железы, рака яичников, меланомы и других раковых опухолей.Международная заявка была опубликована вместе с отчетом о международном поиске.(57) Estramustine phosphate is an antimitotic chemotherapeutic drug with proven efficacy against cancer. This invention describes methods that potentiate the therapeutic benefit of intravenous estramustine phosphate. This invention provides the introduction of intravenous estramustine phosphate in a high dose in excess of 1300 mg, in a single dose. Through this, effective pharmacokinetic estramustine phosphate is achieved. The invention further provides intravenous administration of estramustine phosphate for use in complex programs with another chemotherapeutic agent. The therapeutic benefits achieved with the use of an intravenous composition of estramustine phosphate are applicable to the treatment of various cancers, including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma and other cancers. The international application was published with the international search report.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7954298P | 1998-03-27 | 1998-03-27 | |
| PCT/US1999/004275 WO1999049869A1 (en) | 1998-03-27 | 1999-03-26 | Methods to potentiate intravenous estramustine phosphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA199901081A1 true EA199901081A1 (en) | 2000-12-25 |
| EA004647B1 EA004647B1 (en) | 2004-06-24 |
Family
ID=22151209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199901081A EA004647B1 (en) | 1998-03-27 | 1999-03-26 | Methods of potentiating of intravenous phosphate |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1003521A4 (en) |
| JP (1) | JP2001508810A (en) |
| KR (1) | KR20010021656A (en) |
| CN (2) | CN1636598A (en) |
| AU (1) | AU750010B2 (en) |
| BR (1) | BR9906425A (en) |
| CA (1) | CA2295049A1 (en) |
| EA (1) | EA004647B1 (en) |
| HU (1) | HUP0200547A3 (en) |
| ID (1) | ID24504A (en) |
| IL (1) | IL133612A0 (en) |
| NO (1) | NO20002343L (en) |
| NZ (1) | NZ501987A (en) |
| PL (1) | PL342969A1 (en) |
| WO (1) | WO1999049869A1 (en) |
| ZA (1) | ZA997821B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003201D0 (en) * | 2000-02-11 | 2000-04-05 | Pharmacia & Upjohn Spa | Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| US6436913B1 (en) * | 2000-07-25 | 2002-08-20 | Pharmacia & Upjohn Company | Use of estramustine phosphate in the treatment of bone metastasis |
| RU2471511C1 (en) * | 2011-05-04 | 2013-01-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) | Method of treating colonic liver metastases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617292A (en) * | 1984-06-20 | 1986-01-13 | Japan Atom Energy Res Inst | Method for producing an estracytic compound bound to an anticancer drug |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (en) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS. |
| CA2132711C (en) * | 1992-03-23 | 2005-02-08 | Aquilar Rahman | Liposome encapsulated paclitaxel and a method of using the same |
| FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
-
1999
- 1999-03-26 EP EP99914884A patent/EP1003521A4/en not_active Withdrawn
- 1999-03-26 KR KR1020007000214A patent/KR20010021656A/en not_active Application Discontinuation
- 1999-03-26 CN CNA2004100867183A patent/CN1636598A/en active Pending
- 1999-03-26 BR BR9906425-1A patent/BR9906425A/en not_active IP Right Cessation
- 1999-03-26 NZ NZ501987A patent/NZ501987A/en unknown
- 1999-03-26 EA EA199901081A patent/EA004647B1/en not_active IP Right Cessation
- 1999-03-26 JP JP54936999A patent/JP2001508810A/en not_active Ceased
- 1999-03-26 CN CN99800823A patent/CN1273530A/en active Pending
- 1999-03-26 AU AU33533/99A patent/AU750010B2/en not_active Ceased
- 1999-03-26 WO PCT/US1999/004275 patent/WO1999049869A1/en not_active Application Discontinuation
- 1999-03-26 ID IDW20000105A patent/ID24504A/en unknown
- 1999-03-26 CA CA002295049A patent/CA2295049A1/en not_active Abandoned
- 1999-03-26 IL IL13361299A patent/IL133612A0/en not_active IP Right Cessation
- 1999-03-26 PL PL99342969A patent/PL342969A1/en unknown
- 1999-03-26 HU HU0200547A patent/HUP0200547A3/en unknown
- 1999-12-22 ZA ZA9907821A patent/ZA997821B/en unknown
-
2000
- 2000-05-04 NO NO20002343A patent/NO20002343L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ID24504A (en) | 2000-07-20 |
| AU3353399A (en) | 1999-10-18 |
| CN1636598A (en) | 2005-07-13 |
| CN1273530A (en) | 2000-11-15 |
| KR20010021656A (en) | 2001-03-15 |
| HUP0200547A3 (en) | 2003-07-28 |
| HUP0200547A2 (en) | 2002-07-29 |
| EP1003521A4 (en) | 2003-07-23 |
| EP1003521A1 (en) | 2000-05-31 |
| AU750010B2 (en) | 2002-07-11 |
| NZ501987A (en) | 2002-10-25 |
| IL133612A0 (en) | 2001-04-30 |
| NO20002343D0 (en) | 2000-05-04 |
| EA004647B1 (en) | 2004-06-24 |
| NO20002343L (en) | 2000-05-04 |
| CA2295049A1 (en) | 1999-10-07 |
| BR9906425A (en) | 2000-07-11 |
| PL342969A1 (en) | 2001-07-16 |
| WO1999049869A1 (en) | 1999-10-07 |
| ZA997821B (en) | 2000-08-01 |
| JP2001508810A (en) | 2001-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000282A1 (en) | METHOD OF INTRODUCTION OF A TAXAN TO A PATIENT WHO NEEDS TREATMENT BY A TAXAN, A METHOD OF TREATING A HUMAN BEAM Taksana | |
| BR9807003A (en) | Kit to inhibit the growth of cancers, which comprises a chemotherapeutic agent and benzimedazole, and optionally an enhancer | |
| BR0209147A (en) | Combination therapy using anti-egfr antibodies and antihormonal agents | |
| HK1046093A1 (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers. | |
| MY141584A (en) | Pharmaceutical uses of bisphosphonates | |
| EA200001043A2 (en) | I:npy inhibitor for treating female sexual dysfunction | |
| IL116465A0 (en) | Pharmaceutical antitumor composition | |
| EA200300294A1 (en) | METHODS OF TREATMENT-ASSOCIATED WITH BCL-2 DISORDERS USING BCL-2-ANTISMINAL OLIGOMERS | |
| UA50719C2 (en) | Precursor for therapy of cancer and inflammation | |
| BR9709942A (en) | Use of a compound pharmaceutical composition packaging and treatment process of human or non-human animal organism to combat or prevent conditions associated with the presence of free radicals in the body | |
| DE60143911D1 (en) | ANTITUMOR COMPOSITIONS CONTAINING ECTEINASCIDINE 743 | |
| MXPA04003674A (en) | Improved use of antitumoral compound in cancer therapy. | |
| HUP9802677A2 (en) | Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers | |
| RU2225710C2 (en) | Spisulosine compounds eliciting antitumor activity | |
| BR9814419A (en) | "combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases" | |
| YU77002A (en) | Method and composition for treating cancer by administration oof poptosis-inducing chemotherapeutic agents | |
| EA199901081A1 (en) | METHODS OF POTENTIATION OF INTERNAL STRAUMUSTINPHOSPHATE | |
| EA200100214A1 (en) | APPLICATION OF DERIVATIVES OF CAMPTOTECINE WITH REDUCED GASTROINTESTINAL TOXICITY | |
| ES2300323T3 (en) | COMBINED CHEMOTHERAPY. | |
| HUP0301247A2 (en) | Antitumor therapy comprising distamycin derivatives | |
| BR0214564A (en) | Cancer Treatment Processes Using a Fpt Inhibitor and Antineoplastic Agents | |
| CA2368676A1 (en) | Sphingomyelin containing preparation | |
| CA2343120A1 (en) | Use of an anthracycline derivative for the treatment of a liver tumor | |
| WO2002017962A3 (en) | Chemoprotectant for gastric toxicity | |
| EA200100311A1 (en) | Bifunctional antibodies and their application for targeted delivery of antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |